GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials

GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials

The incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are released from enteroendocrine cells in response to the presence of nutrients in the small intestines. These homones facilitate glucose regulation by stimulating insulin secretion in a glu...

Full description

Bibliographic Details
Main Authors: Matthew P. Gilbert, Richard E. Pratley
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-04-01
Series:Frontiers in Endocrinology
Subjects:
incretin hormones
GLP-1 receptor agonists
DPP-4 inhibitors
cardiovascular outcomes trials
clinical trials
incretin biology
Online Access:https://www.frontiersin.org/article/10.3389/fendo.2020.00178/full

Internet

https://www.frontiersin.org/article/10.3389/fendo.2020.00178/full

Similar Items